Last reviewed · How we verify

Arelix (PIRETANIDE)

FDA-approved active Small molecule Quality 26/100

Piretanide (Arelix) is a marketed diuretic used primarily for the treatment of edema, competing in a class dominated by long-standing drugs such as furosemide, bumetanide, and torsemide. Its key strength lies in its mechanism of action, which effectively blocks the sodium-potassium-chloride cotransporter in the kidneys, potentially offering a more targeted approach to fluid management. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic namePIRETANIDE
Drug classpiretanide
TargetSolute carrier family 12 member 1
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: